Some treatments are worth it per patient but hard to fund for everyone.
Module Focus
Imagine a medicine that actually works. People feel better, live longer, and avoid complications. Now imagine that medicine is expensive, and a lot of people qualify for it.
Even if it is a good deal for each patient, the total bill can be so large that a program cannot pay for everyone at once.
In this module, you will learn a simple way to answer two questions separately:
Is it worth it for one patient?
This is a question about value.
Can we pay for it for everyone?
This is a question about budget.
You will practice with a GLP-1 case and then make a funding decision in a Shark Tank activity.
Learning Targets
By the end of this module, you should be able to:
Compute a simple cost per health gained number using provided data.
Explain the difference between good value and too expensive at scale using one example.
Make a funding decision under scarcity and defend it with three points: value, budget impact, and who benefits.
Check Your Understanding
A treatment has a low cost per QALY but is needed by millions of people. Which statement is most accurate?
Cost-effectiveness and affordability are two separate questions. A treatment can be good value per patient while still creating a budget problem when multiplied across thousands or millions of eligible patients.
Why does scarcity make funding decisions harder than simply asking "does this treatment work?"
Scarcity means budgets are limited. Even if a treatment clearly works, covering it may mean cutting something else. That is why policymakers need to weigh both value and budget impact, not just effectiveness.
1) The Core Problem: The Price of Progress
Medical innovation saves lives and improves quality of life. But it creates a hard question:
If a new treatment works, who should pay for it, and how much is reasonable?
Public programs, hospitals, and school districts do not have unlimited money. Funding one expensive thing often means not funding something else. That is why we need a decision tool, not just opinions.
Innovation
New treatments save lives and reduce suffering.
High cost
Development is expensive and risky. Prices reflect that.
Scarcity
Budgets are limited. Funding one thing can crowd out another.
2) A Simple Tool: Cost-Effectiveness (CEA)
Cost-effectiveness asks one basic question:
How much health do we get per dollar?
It does not answer everything, but it helps you compare options using a common metric.
The simplest ratio (CER)
CER=Cost of intervention÷Health benefit
Incremental version (ICER)
ICER=(Cost new − Cost old)÷(Benefit new − Benefit old)
Translation: How much extra money for how much extra health?
CER comparison — lower is better value
Cost per QALY gained ($ per QALY)
$120kLow benefit
high cost
$60kGLP-1
(this case)
$15kHigh benefit
low cost
3) What Is a QALY?
A QALY stands for Quality-Adjusted Life Year. Think of it as one year of life in perfect health.
1.0 QALY
One full year in perfect health.
0.5 QALY
One year in health that is half as good — because of pain, disability, or severe symptoms.
QALY as a health scale
Perfect health
1.0
Managed chronic
0.75
Significant pain
0.5
Severe illness
0.25
You do not need to debate the philosophy today. We use QALYs because they let us compare different health outcomes using one common scale.
4) Cost-Effective vs. Affordable
These are not the same thing.
Cost-effective
Good value per unit of health. If a drug gives a big health benefit relative to its cost, it can be cost-effective.
Affordable
The total bill fits the budget. Even a cost-effective drug can be unaffordable if a lot of people need it.
The formula that connects them
Budget impact≈Cost per patient×Number of patients
So the same drug can be good value per patient but impossible to fund for everyone at once.
Budget impact grows with eligible patients
Net cost per patient = $3,600 · Total impact in $ millions
$36M10k
$72M20k
$144M40k
$288M80k
(GLP-1)
GLP-1 case dashed line at $288M (largest bar)
5) Why Do Drugs Cost So Much?
Drug development is risky and expensive. A lot of candidates fail. Patents and exclusivity are designed to encourage companies to invest by giving them a period with less competition.
R&D is expensive and risky. Most drug candidates never make it to market. Companies must price successes to recover failures too.
Patents protect the payoff. A patent gives the developer a period of market exclusivity — time to earn back their investment.
High demand can mean high prices. When many people need a drug and alternatives are limited, prices can be set very high.
You do not need to memorize the law. Just understand the incentive: higher expected reward can lead to more investment, but also higher prices.
Case Study
GLP-1 Budget Breaker
What are GLP-1 drugs?
GLP-1 drugs can help with weight loss and can improve metabolic health. Demand is high because obesity is common and the health benefits can be meaningful for many patients.
The policy conflict
Even if a program negotiates a lower price or sets a cap, states may still restrict coverage because:
Many eligible patients × high cost per patient = huge total spending
Budgets are limited and states must balance multiple priorities
Scenario
A state Medicaid program is considering expanding coverage for a GLP-1 drug. A negotiated or capped price exists in some settings, but the state still fears the budget impact.
Given numbers
Item
Value
Cost of GLP-1 per patient per year
$4,200
Expected health benefit per patient per year
0.06 QALYs
Expected avoided medical costs per patient per year
$600
Eligible patients in the state
80,000
Worked calculations
Net cost per patient$4,200 − $600 = $3,600
CER (cost per QALY)$3,600 ÷ 0.06 = $60,000 / QALY
Budget impact per year$3,600 × 80,000 = $288,000,000
Discussion prompt
Is it possible for something to be good value and still too expensive? Use the numbers.
Check Your Understanding
Using the GLP-1 case numbers, what is the net cost per patient per year?
Net cost = drug cost minus the medical costs avoided. $4,200 − $600 = $3,600. This is what the program actually pays per patient after accounting for the savings from avoided care.
What is the CER (cost per QALY) for the GLP-1 drug in this case?
CER = net cost ÷ health benefit = $3,600 ÷ 0.06 QALYs = $60,000 per QALY. By common benchmarks, this is often considered in the range of acceptable value, though reasonable people disagree on the exact threshold.
What is the total budget impact per year if all 80,000 eligible patients are covered?
Budget impact = net cost per patient × number of patients = $3,600 × 80,000 = $288,000,000. Even though the value per patient is reasonable, the total bill at scale is very large.
Activity
Shark Tank: Fund It or Cut It
Goal
Make a funding decision under scarcity and defend it with three points: value, budget impact, and who benefits.
The Setup
You are on the state Medicaid budget committee. You have a fixed budget for new programs this year. Three proposals are on the table. You can fully fund one, partially fund one, or reject one. You cannot fund all three.
Program
Cost / patient
Patients
QALYs / patient
Total cost
GLP-1 drug (weight loss)
$3,600
80,000
0.06
$288M
Diabetes prevention program
$500
20,000
0.10
$10M
Mental health counseling
$1,200
30,000
0.15
$36M
Your Task
Compute the CER for each program (net cost ÷ QALYs per patient).
Rank the three programs by value (lowest CER = best value per health gained).
Decide: which do you fully fund, partially fund, and reject?
Write a 3-point defense: value, budget impact, and who benefits.
Debrief
Which program had the best CER? Does that automatically mean it should be fully funded?
Did budget impact change your ranking? Why or why not?
Which group of patients loses out in your decision, and how would you explain that to them?
Check Your Understanding
Which of the three programs has the best CER (lowest cost per QALY)?
CER = cost per patient ÷ QALYs per patient. Diabetes prevention: $500 ÷ 0.10 = $5,000 per QALY. Mental health: $1,200 ÷ 0.15 = $8,000 per QALY. GLP-1: $3,600 ÷ 0.06 = $60,000 per QALY. Diabetes prevention gives the most health per dollar.
The diabetes prevention program has the best CER. Should that automatically mean it gets the most funding?
CER is a useful tool but not the only one. A complete funding decision also considers total budget impact, who the patients are, equity concerns, and whether some groups are systematically underserved. Best value per QALY is a strong argument but not the whole story.